Search Results - "PETERSDORF, Stephen H"

Age and acute myeloid leukemia by Appelbaum, Frederick R., Gundacker, Holly, Head, David R., Slovak, Marilyn L., Willman, Cheryl L., Godwin, John E., Anderson, Jeanne E., Petersdorf, Stephen H.

“…We conducted a retrospective analysis of 968 adults with acute myeloid leukemia (AML) on 5 recent Southwest Oncology Group trials to understand how the nature…”
Get full text

Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI by Othus, Megan, van Putten, Wim, Lowenberg, Bob, Petersdorf, Stephen H, Nand, Sucha, Erba, Harry, Appelbaum, Frederick, Hills, Robert, Russell, Nigel, Burnett, Alan, Estey, Elihu

Get full text

High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults ≥ 60 Years Old With Relapsed or Refractory B-Cell Lymphoma by GOPAL, Ajay K, RAJENDRAN, Joseph G, GOOLEY, Ted A, PAGEL, John M, FISHER, Darrell R, PETERSDORF, Stephen H, MALONEY, David G, EARY, Janet F, APPELBAUM, Frederick R, PRESS, Oliver W

“…The majority of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) are older than 60 years, yet they are often denied potentially…”
Get full text

Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG by Walter, Roland B, Othus, Megan, Löwenberg, Bob, Ossenkoppele, Gert J, Petersdorf, Stephen H, Pabst, Thomas, Vekemans, Marie-Christiane, Appelbaum, Frederick R, Erba, Harry P, Estey, Elihu H

Get full text

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis by Gopal, Ajay K., Gooley, Theodore A., Maloney, David G., Petersdorf, Stephen H., Eary, Janet F., Rajendran, Joseph G., Bush, Sharon A., Durack, Lawrence D., Golden, Jane, Martin, Paul J., Matthews, Dana C., Appelbaum, Frederick R., Bernstein, Irwin D., Press, Oliver W.

“…We performed a multivariable comparison of 125 consecutive patients with follicular lymphoma (FL) treated at our centers with either high-dose…”
Get full text

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia by Petersdorf, Stephen H., Kopecky, Kenneth J., Slovak, Marilyn, Willman, Cheryl, Nevill, Thomas, Brandwein, Joseph, Larson, Richard A., Erba, Harry P., Stiff, Patrick J., Stuart, Robert K., Walter, Roland B., Tallman, Martin S., Stenke, Leif, Appelbaum, Frederick R.

“…This randomized phase 3 clinical trial evaluated the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and…”
Get full text

Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report by Ostronoff, Fabiana, Othus, Megan, Lazenby, Michelle, Estey, Elihu, Appelbaum, Frederick R, Evans, Anna, Godwin, John, Gilkes, Amanda, Kopecky, Kenneth J, Burnett, Alan, List, Alan F, Fang, Min, Oehler, Vivian G, Petersdorf, Stephen H, Pogosova-Agadjanyan, Era L, Radich, Jerald P, Willman, Cheryl L, Meshinchi, Soheil, Stirewalt, Derek L

“…Younger patients with acute myeloid leukemia (AML) harboring NPM1 mutations without FLT3-internal tandem duplications (ITDs; NPM1-positive/FLT3-ITD-negative…”
Get full text

Clofarabine with high dose cytarabine and granulocyte colony‐stimulating factor (G‐CSF) priming for relapsed and refractory acute myeloid leukaemia by Becker, Pamela S., Kantarjian, Hagop M., Appelbaum, Frederick R., Petersdorf, Stephen H., Storer, Barry, Pierce, Sherry, Shan, Jianqin, Hendrie, Paul C., Pagel, John M., Shustov, Andrei R., Stirewalt, Derek L., Faderl, Stephan, Harrington, Elizabeth, Estey, Elihu H.

“…Summary This phase I/II study was conducted to determine the maximum tolerated dose, toxicity, and efficacy of clofarabine in combination with high dose…”
Get full text

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia by Michelson, Andrew P., McDonough, Shannon, Willman, Cheryl L., Koegle, Eric R., Godwin, John E., Petersdorf, Stephen H., List, Alan F., Othus, Megan, Appelbaum, Frederick R., Radich, Jerald P., Ganapathi, Mahrukh K., Advani, Anjali S., Ganapathi, Ram N.

“…Anthracyclines used in the treatment of acute myelogenous leukemia (AML) inhibit the activity of the mammalian topoisomerase II (topo II) isoforms, topo II α…”
Get full text

Senior adult oncology by Hurria, Arti, Browner, Ilene S, Cohen, Harvey Jay, Denlinger, Crystal S, deShazo, Mollie, Extermann, Martine, Ganti, Apar Kishor P, Holland, Jimmie C, Holmes, Holly M, Karlekar, Mohana B, Keating, Nancy L, McKoy, June, Medeiros, Bruno C, Mrozek, Ewa, O'Connor, Tracey, Petersdorf, Stephen H, Rugo, Hope S, Silliman, Rebecca A, Tew, William P, Walter, Louise C, Weir, 3rd, Alva B, Wildes, Tanya

Get more information

Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia by Becker, Pamela S., Kopecky, Kenneth J., Wilks, Adrianne N., Chien, Sylvia, Harlan, John M., Willman, Cheryl L., Petersdorf, Stephen H., Stirewalt, Derek L., Papayannopoulou, Thalia, Appelbaum, Frederick R.

“…Adhesion of acute myeloid leukemia (AML) blasts in the bone marrow microenvironment confers protection from chemotherapy-induced apoptosis. One mechanism for…”
Get full text

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG by Ho, Phoenix A., Kopecky, Kenneth J., Alonzo, Todd A., Gerbing, Robert B., Miller, Kristen L., Kuhn, Julia, Zeng, Rong, Ries, Rhonda E., Raimondi, Susana C., Hirsch, Betsy A., Oehler, Vivian, Hurwitz, Craig A., Franklin, Janet L., Gamis, Alan S., Petersdorf, Stephen H., Anderson, Jeanne E., Godwin, John E., Reaman, Gregory H., Willman, Cheryl L., Bernstein, Irwin D., Radich, Jerald P., Appelbaum, Frederick R., Stirewalt, Derek L., Meshinchi, Soheil

“…IDH1 SNP rs11554137 was recently reported in association with poor prognosis in normal karyotype adult acute myeloid leukemia (AML). We aimed to determine the…”
Get full text

Acute lymphoblastic leukemia by Alvarnas, Joseph C, Brown, Patrick A, Aoun, Patricia, Ballen, Karen Kuhn, Bellam, Naresh, Blum, William, Boyer, Michael W, Carraway, Hetty E, Coccia, Peter F, Coutre, Steven E, Cultrera, Jennifer, Damon, Lloyd E, DeAngelo, Daniel J, Douer, Dan, Frangoul, Haydar, Frankfurt, Olga, Goorha, Salil, Millenson, Michael M, O'Brien, Susan, Petersdorf, Stephen H, Rao, Arati V, Terezakis, Stephanie, Uy, Geoffrey, Wetzler, Meir, Zelenetz, Andrew D, Naganuma, Maoko, Gregory, Kristina M

“…The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings…”
Get more information

High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin Lymphoma : The Seattle Experience by GOPAL, Ajay K, METCALFE, Tracee L, GOOLEY, Ted A, PAGEL, John M, PETERSDORF, Stephen H, BENSINGER, William I, HOLMBERG, Leona, MALONEY, David G, PRESS, Oliver W

“…High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the standard treatment for patients with chemosensitive relapsed/refractory Hodgkin…”
Get full text

Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium by Gopal, Ajay K., Press, Oliver W., Shustov, Andrei R., Petersdorf, Stephen H., Gooley, Ted A., Daniels, Jasmine T., Garrison, Mitchell A., Gjerset, George F., Lonergan, Matthew, Murphy, Anne E., Smith, Julie C., Pagel, John M.

“…We conducted a multi-center phase II trial of gemcitabine (G), carboplatin (C), dexamethasone (D), and rituximab (R) in order to examine its safety and…”
Get full text

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma by Gopal, Ajay K., Rajendran, Joseph G., Petersdorf, Stephen H., Maloney, David G., Eary, Janet F., Wood, Brent L., Gooley, Theodore A., Bush, Sharon A., Durack, Lawrence D., Martin, Paul J., Matthews, Dana C., Appelbaum, Frederick R., Bernstein, Irwin D., Press, Oliver W.

“…Relapsed mantle cell lymphoma is a radiation-sensitive malignancy that is unlikely to be cured by treatment with conventional high-dose therapy and autologous…”
Get full text

A model for prediction of FLT3‐ITD and NPM1 (without FLT3‐ITD) positivity in patients with newly diagnosed acute myeloid leukaemia by Ostronoff, Fabiana, Othus, Megan, Kantarjian, Hagop M., Meshinchi, Soheil, Ravandi, Farhad, Hendrie, Paul C., Faderl, Stefan, Becker, Pamela S., Cortes, Jorge E., Pagel, John M., Petersdorf, Stephen H., Godwin, John E., Willman, Cheryl L., Pierce, Sherry A., List, Alan F., Sandhu, Ravinder K., Walter, Roland B., Stirewalt, Derek L., Appelbaum, Frederick R., Estey, Elihu H.

Get full text

A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation by Inamoto, Yoshihiro, Fefer, Alexander, Sandmaier, Brenda M, Gooley, Theodore A, Warren, Edus H, Petersdorf, Stephen H, Sanders, Jean E, Storb, Rainer F, Appelbaum, Frederick R, Martin, Paul J, Flowers, Mary E.D

“…The efficacy of donor lymphocyte infusion (DLI) for treatment of relapsed acute leukemia after allogeneic hematopoietic cell transplantation is limited. We…”
Get full text

Senior adult oncology clinical practice guidelines in oncology by Balducci, Lodovico, Cohen, Harvey Jay, Engstrom, Paul F, Ettinger, David S, Halter, Jeffrey, Gordon, Leo I, Kiel, Krystyna, Kneier, Andrew, Lim, Dean, Petersdorf, Stephen H, Rosenthal, Ronnie, Silliman, Rebecca, Vose, Julie M, Walker, Michael J, Zachariah, Babu

Get more information

Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma by Till, Brian G., Gooley, Theodore A., Crawford, Nathan, Gopal, Ajay K., Maloney, David G., Petersdorf, Stephen H., Pagel, John M., Holmberg, Leona, Bensinger, William, Press, Oliver W.

“…We analysed the outcomes of autologous stem cell transplantation (ASCT) following high-dose therapy with respect to remission status at the time of…”
Get full text